Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome.
Kapiteijn
E
E
Brand
A
A
Kroep
J
J
Gelderblom
H
H
D000970:Antineoplastic Agents / Q000009:adverse effects*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000139:chemically induced*; D007211:Indoles / Q000009:adverse effects*; D008875:Middle Aged; D020258:Neurotoxicity Syndromes / Q000209:etiology*; D011697:Purpura, Thrombotic Thrombocytopenic / Q000139:chemically induced*; D011758:Pyrroles / Q000009:adverse effects*; D000077210:Sunitinib; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D040301:Vascular Endothelial Growth Factor Receptor-2 / Q000037:antagonists & inhibitors
D000970:Antineoplastic Agents; D007211:Indoles; D011758:Pyrroles; D042461:Vascular Endothelial Growth Factor A; D040301:Vascular Endothelial Growth Factor Receptor-2; D000077210:Sunitinib